FDA018-ADC

DRUG2 trials

Sponsors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Conditions

Advanced/ Metastatic Solid TumorsTriple Negative Breast Cancer

Phase 1

A Study of FDA018-ADC in Patients With Advanced Solid Tumors

Active, not recruitingNCT05174637

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Advanced/ Metastatic Solid Tumors

Start: 2021-10-22End: 2029-12-01Target: 78Updated: 2026-01-23

Phase 3

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Active, not recruitingNCT06519370

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Triple Negative Breast Cancer

Start: 2024-08-09End: 2027-06-20Target: 350Updated: 2026-01-22

Related Papers

Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2024-06-01